中国临床药理学杂志

[1] 任爽，李大江，胡果.医院规范化静脉血栓栓塞症防治与管理体系的建立[J].华西医学，2017,32(2):258-261.

[2] 季建峰，戴春雷，储晓彬.PDCA循环在防治静脉血栓栓塞症精细化管理中的应用[J].江苏卫生事业管理，2018,164(4):45-46,49.

[3] 杨林，董文伟，胡建利，等.多团队协作护理预防髋关节置换术患者下肢深静脉血栓[J].中国现代医生，2018,56(36):142-145.

[4] 严晓霞，刘虹婷，陈蓓，等.多学科合作品管圈活动在降低肺癌围术期肺栓塞发生率中的应用[J].解放军护理杂志，2019,36(3):88-92.

[5] 赵建美，倪松石，仇永贵，等.我院静脉血栓栓塞症防治管理体系的构建与实施[J].江苏卫生事业管理，2014,25(1):45-46.

[6] 沈忱，李惠玲，顾洁，等.基于多学科一体化的静脉血栓防治实践与探讨[J].中国现代医生，2018,56(36):142-145.

[7] 宁宁，李佩芳，屈俊宏，等.项目管理在脊柱骨折患者围手术期DVT防控中的效果研究[J].中国护理管理，2017,17(11):1445-1450.

[8] CARDOSO L F,KROKOSCZ D V C,EDISON FERREIRA DE PAIVA 1 I S F I,et al.Results of a venous thromboembolism prophylaxis program for hospitalized patients[J].Vasc Health Risk Manag,2016,12(1):491-496.

[9] CRONIN M,HILL T,REICH D A,et al.Implementation of a multidisciplinary,pharmacy-led,thromboprophylaxis program in total-joint arthroplasty patients[J].Am J Health Syst Pharm,2009,66(2):171-175.

[10] 刘荣玲，武丽锳，阮明珠，等.医师-药师协作模式在静脉血栓栓塞症患者治疗中的临床研究[J].中国实用医药，2016,11(35):182-184.

[11] 李鑫，茆玲，林敏，等.利伐沙班与低分子肝素对髋膝关节置换术后下肢深静脉血栓预防的应用评价[J].蚌埠医学院学报，2018,43(12):31-34.

[12] 艳丽，丁亮，焦萍，等.临床药师干预骨科大手术患者预防深静脉血栓效果评价[J].中国药物应用与监测，2018,15(5):307-310.

[13] BAUER J B,CHUN D S,KARPINSK T A.Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital[J].Am J Health Syst Pharm,2008,65(17):1643-1647.

[14] COLE J L,STARK J E.A facility mandate for pharmacist assessment improves venous thromboembolism outcomes[J].J Am Coll Clin Pharm,2019,2(1):274-280.

[15] CUERVO C G,PARDO O B,ASíN M A P.Efficacy and safety of the use of heparin as thromboprophylaxis in patients with liver cirrhosis:A systematic review and meta-analysis[J].Thromb Res,2013,132(4):414-419.

[16] VILLA E,CAMMà C,MARIETTA M,et al.Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J].Gastroenterology,2012,143(5):1253-1260.

[17] NAPOLITANO M,SACCULLO G,MARIETTA M,et al.Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism:an expert consensus[J].Blood Transfus,2019,17(3):171-180.

[18] KHANAL N,BOCIEK R G,CHEN B,et al.Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia[J].Am J Hematol,2016,91(11):468-472.

[19] BANNOW B T S,WALTER R B,GERNSHEIMER T B,et al.Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes[J].J Thromb Thrombolysis,2017,44(4):442-447.

[20] STREIFF M B,HOLMSTROM B,ANGELINI D,et al.NCCN guidelines insights:Cancer-associated venous thromboembolic disease,Version 2.2018[J].J Natl Compr Canc Netw,2018,16(11):1289-1303.

[21] BANNOW B R S,LEE A Y Y,KHORANA A A,et al.Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia:A systematic review[J].Res Pract Thromb Haemost,2018,2(4):664-669.

[22] ATHER S,SHENDRE A,BEASLEY T M,et al.Effect of left ventricular systolic dysfunction on response to warfarin[J].Am J Cardiol,2016,118(2):232-236.

[23] BELCH J J,LOWE G D,WARD A G,et al.Prevention of deep vein thrombosis in medical patients by low-dose heparin[J].Scott Med J,1981,26(2):115-117.

[24] TEBBE U,SCHELLONG S M,HAAS S,et al.Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure:a subgroup analysis of the randomized,controlled CERTIFY study[J].Am Heart J,2011,161(2):322-328.

[25] HULL R D,SCHELLONG S M,TAPSON V F,et al.Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility:A randomized trial[J].Ann Intern Med,2010,153(1):8-18.

[26] GOLDHABER S Z,LEIZOROVICZ A,KAKKAR A K,et al.Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients[J].N Engl J Med,2011,365(23):2167-2177.

[27] COHEN A T,SPIRO T E,BüLLER H R,et al.Rivaroxaban for thromboprophylaxis in acutely ill medical patients[J].N Engl J Med,2013,368(6):513-523.

[28] COHEN A T,HARRINGTON R A,GOLDHABER S Z,et al.Extended thromboprophylaxis with betrixaban in acutely Ⅲ medical patients[J].N Engl J Med,2016,375(6):534-544.

[29] COHEN A T,DAVIDSON B L,GALLUS A S,et al.Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients:randomised placebo controlled trial[J].BMJ,2006,332(7537):325-329.

[30] KONSTANTINIDES S V,MEYER G,BECATTINI C,et al.2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS):The task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)[J].Eur Respir J,2019,54(3):1901647.

[31] LONDON:NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (UK).Venous thromboembolic diseases:diagnosis,management and thrombophilia testing[J/OL].Nat Institute Health Care Excellence Clin Guidelines,2020,e1-e47.2020-03-26[2021-02-19].https://www.nice.org.uk/guidance/ng158/resources/venous-thromboembolic-diseases-diagnosis-management-and-thrombophilia-testing-pdf-66141847001797.

[32] 赵玉沛，秦新裕.中国普通外科围手术期血栓预防与管理指南[J].中华外科杂志，2016,8(2):57-62.

[33] 马军，吴一龙，秦叔逵.肿瘤相关静脉血栓栓塞症的预防与治疗中国专家指南(2015版)[J].中国肿瘤临床，2016,43(7):274.

[34] 杨勇，肖长青，李恩，等.低分子肝素钙与利法沙班预防老年股骨转子间骨折围手术期深静脉血栓形成的疗效对比[J].临床医药文献电子杂志，2019,365(48):157-158.

[35] ALTORJAYá,SZABó é,BODA Z,et al.Effects of long-term low-molecular-weight heparin on fractures and bone density in non-pregnant adults:A systematic review with meta-analysis[J].Thromb Res,2016,31(8):947-957.

[36] 张辉良，梁俊生，张洪斌，等.低分子肝素预防老年髋部骨折患者下肢深静脉血栓的疗效分析[J].实用临床医药杂志，2013,17(5):129-130.

[37] GREER I A,NELSON-PIERCY C.Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy:a systematic review of safety and efficacy[J].Blood,2005,106(2):401-407.

[38] ROMUALDI E,DENTALI F,RANCAN E,et al.Anticoagulant therapy for venous thromboembolism during pregnancy:A systematic review and a meta-analysis of the literature[J].J Thromb Haemost,2013,11(2):270-281.

[39] QUEENSLAND CLINICAL GUIDELINES.Venous thromboembolism (VTE) in pregnancy and pregnancy and the puerperium [J/OL].Queensland Health,2020:e1-e24.2020-08-24[2021-04-08].https://www.health.qld.gov.au/__data/assets/pdf_file/0011/140024/g-vte.pdf.

[40] BATES S M,GREER I A,MIDDELDORP S,et al.VTE,thrombophilia,antithrombotic therapy,and pregnancy:Antithrombotic therapy and prevention of thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl):S691-S736.

[41] WEE-SHIAN CHAN 1 E R,KENT N E,GROUP V I P G W.Venous thromboembolism and antithrombotic therapy in pregnancy[J].J Obstet Gynaecol Can,2014,36(6):527-553.

[42] MALE C,LENSING A W A,PALUMBO J S,et al.Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children:a randomised,controlled,phase 3 trial[J].Lancet Haematol,2020,7(1):18-27.

[43] 周艳红，叶爱武.影响华法林疗效的原因分析及护理[J].护理实践与研究，2012,9(12):92-93.

[44] MEDJERAL-THOMAS N,ZIAJ S,MARIE CONDON J G,et al.Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome[J].Clin J Am Soc Nephrol,2014,9(3):478-483.

[45] ROSTOKER G,DURAND-ZALESKI I,PETIT-PHAR M,et al.Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin[J].Nephron,1995,69(1):20.

[46] 殷红梅，刘辉，曹莹莹.利伐沙班与华法林在肾病综合症患者预防深静脉血栓形成的比较研究[J].中外健康文摘，2013,9(34):134-135.

[47] 袁小强.抗凝疗法在86例原发性肾病综合征中应用[J].中国医疗前沿，2008,3(21):86.

[48] 张晓江，颜红兵，迟云鹏，等.华法林维持抗凝与桥接抗凝在冠状动脉介入治疗患者中的安全性比较[J].中华心血管病杂志，2018,46(7):549-553.

[49] 何源，窦克非.口服抗凝药物患者经皮冠状动脉介入治疗围术期抗凝治疗的研究进展[J].中国循环杂志，2016,31(8):813-816.

[50] KARJALAINEN P P,VIKMAN S,NIEMEL? M,et al.Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment[J].Eur Heart J,2008,29(8):1001-1010.

[51] HELFT G,DAMBRIN G,ZAMAN A,et al.Percutaneous coronary intervention in anticoagulated patients via radial artery access[J].Catheter Cardiovasc Interv,2009,73(1):44-47.

[52] GEERTS W H,PINEO G F,HEIT J A,et al.Prevention of venous thromboembolism:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,2004(3 Suppl):S338- S400.

[53] 田伟.中国骨科大手术静脉血栓栓塞症预防指南[J].中华骨科杂志，2016,36(2):65-71.

[54] SOBIERAJ D M,LEE S,COLEMAN C I,et al.Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery:A systematic review[J].Ann Intern Med,2012,156(10):720-727.

[55] BAKKER X R,ROUMEN R M H.Bleeding after excision of breast lumps[J].Eur J Surg,2002,168(7):401-403.

[56] BASSIRI-TEHRANI B,KARANETZ I,BERNIK S F,et al.The timing of chemoprophylaxis in autologous microsurgical breast reconstruction[J].Plast Reconstr Surg,2018,142(5):1116-1123.

[57] DELMAURO M A,CHEN K,KELLER A.Reducing length of stay after microsurgical breast reconstruction with a standardized postoperative protocol[J].J Reconstr Microsurg,2019,35(8):557-567.

[58] HARDY R G,WILLIAMS L,DIXON J M.Use of enoxaparin results in more haemorrhagic complications after breast surgery than unfractionated heparin[J].Br J Surg,2008,95(7):834-836.

[59] TEMPELHOFF G F V,HARENBERG J,NIEMANN F,et al.Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery:Efficacy,safety,and follow-up[J].Clin Applied Thromb Hemost,1998,4(4):268-273.

[60] KEITH J N,CHONG T W,DAVAR D,et al.The timing of preo-perative prophylactic low-molecular-weight heparin administration in breast reconstruction[J].Plast Reconstr Surg,2013,132(2):279-284.

[61] KIM E K,EOM J S,AHN S H,et al.The efficacy of prophylactic low-molecular-weight heparin to prevent pulmonary thromboembolism in immediate breast reconstruction using the TRAM flap[J].Plast Reconstr Surg,2009,123(1):9-12.

[62] LAPID O,PIETERSEN L,VAN DER HORST C M.Reoperation for haematoma after breast reductionwith preoperative administration of low-molecular-weight heparin:Experience in 720 patients[J].J Plast Reconstr Aesthet Surg,2012,65(11):1513-1517.

[63] LAWS A,ANDERSON K,HU J,et al.Implementation of a venous thromboembolism prophylaxis protocol using the caprini risk assessment model in patients undergoing mastectomy[J].Ann Surg Oncol,2018,25(12):3548-3555.

[64] LIAO E C,TAGHINIA A H,NGUYEN L P,et al.Incidence of hematoma complication with heparin venous thrombosis prophylaxis after TRAM flap breast reconstruction[J].Plast Reconstr Surg,2008,121(4):1101-1107.

[65] LEMAINE V,MCCARTHY C,KAPLAN K,et al.Venous thromboembolism following microsurgical breast reconstruction:An objective analysis in 225 consecutive patients using low-molecular-weight heparin prophylaxis[J].Plast Reconstr Surg,2011,127(4):1399-1406.

[66] 瞿红，张震宇.妇科围手术期静脉血栓栓塞症的预防[J].中国实用妇科与产科杂志，2018,34(7):717-720.

[67] MURTHY S B,GUPTA A,MERKLER A E,et al.Restarting anticoagulant therapy after intracranial hemorrhage:A systematic review and meta-analysis[J].Stroke,2017,48(6):1594-1600.

[68] 倪杰，钱健，王路娜，等.低分子肝素预防脑出血后深静脉血栓有效性和安全性研究[J].中国卒中杂志，2018,13(6):562-566.

[69] 陈敢.早期低分子肝素应用预防脑出血患者下肢深静脉血栓的疗效观察[J].双足与保健，2019,28(1):33-34.

[70] PACIARONI M,AGNELLI G,VENTI M,et al.Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage:A meta-analysis of controlled studies[J].J Thromb Haemost,2011,9(5):893-898.

[71] STEFFEL J,COLLINS R,ANTZ M,et al.2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J/OL].Europace,2021:e65.2021-04-25[2021-05-23].https://pubmed.ncbi.nlm.nih.gov/33895845/.

[72] MCCARTHY S T,TURNER J.Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke[J].Age Ageing,1986,15(2):84-88.

[73] MCCARTHY S T,TURNER J J,ROBERTSON D,et al.Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke[J].Lancet,1977,2(8042):800-801.

[74] KELLY J,LEWIS R.Heparin thromboprophylaxis after acute stroke[J].Age Ageing,2001,30(1):89-90.

[75] ELIAS A,MILANDRE L,LAGRANGE G,et al.Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction:a randomized pilot study (30 patients)[J].Rev Med Interne,1990,11(1):95-98.

[76] TURPIE A G.Orgaran in the prevention of deep vein thrombosis in stroke patients[J].Haemostasis,1992,22(2):92-98.

[77] KNUDSON M M,IKOSSI D G,KHAW L,et al.Thromboembolism after trauma:an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank[J].Ann Surg,2004,240(3):490-496.

[78] MOHSENI S,TALVING P,LAM L,et al.Venous thromboembolic events in isolated severe traumatic brain injury[J].J Emerg Trauma Shock,2012,5(1):11-15.

[79] DALEY M J,ALI S,BROWN C V R.Late venous thromboembolism prophylaxis after craniotomy in acute traumatic brain injury[J].Am Surg,2015,81(2):207-211.

[80] SCUDDAY T,BRASE K,WEBB T,et al.Safety and efficacy of prophylactic anticoagulation in patients with traumatic brain injury[J].J Am Coll Surg,2011,213(1):148-153.

[81] KWIATT M E,PATEL M S,ROSS S E,et al.Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury?A Western Trauma Association multicenter study[J].J Trauma Acute Care Surg,2012,73(3):625-628.

[82] 刘福兴，贾战斗，张唯，等.弹簧圈栓塞颅内动脉瘤结合低分子肝素治疗蛛网膜下腔出血[J].脑与神经疾病杂志，2005,13(3):226-227.

[83] 解锋，李旭华.抗血小板药物和抗凝药物在破裂动脉瘤支架辅助栓塞中的应用价值[J].中国实用神经疾病杂志，2016,19(3):118-119.

[84] 王培明，周立云，连宗德，等.破裂动脉瘤支架辅助栓塞中抗血小板药物和抗凝药物的使用分析[J].中国医学工程，2016,24(3):60-61.

[85] LAWTON M T,VATES G E.Subarachnoid hemorrhage[J].N Engl J Med,2017,377(3):257-266.

[86] 李钢，李保东，马春晓.低分子量肝素预防脑肿瘤术后下肢深静脉血栓形成的临床分析[J].中国医药，2008,3(4):227-228.

[87] CONSTANTINI S,KANNER A,FRIEDMAN A,et al.Safety of perioperative minidose heparin in patients undergoing brain tumor surgery:a prospective,randomized,double-blind study[J].J Neurosurg,2001,94(94):918-921.

[88] EISENRING C V,NEIDERT M C,BOVé D S,et al.Reduction of thromboembolic events in meningioma surgery:a cohort study of 724 consecutive patients[J/OL].PLoS One,2013,8(11):e1-e8.2013-11-14[2021-02-13].https://pubmed.ncbi.nlm.nih.gov/24244441/.

[89] SMITH T R,LALL R R,GRAHAM R B,et al.Venous thromboembolism in high grade glioma among surgical patients:Results from a single center over a 10 year period[J].J Neurooncol,2014,120(2):347-352.

[90] SJ?VIK K,BARTEK J JR,SOLHEIM O,et al.Venous thromboembolism prophylaxis in meningioma surgery:A population-based comparative effectiveness study of routine mechanical prophylaxis with or without preoperative low-molecular-weight heparin[J/OL].World Neurosurg,2015,88:e320-e326.2015-11-31[2021-05-21].https://pubmed.ncbi.nlm.nih.gov/26746334.

[91] KIM B J,DAY R W,DAVIS C H,et al.Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective[J].J Thromb Haemost,2017,15(11):2158-2164.

[92] IMAMURA H,ADACHI T,KITASATO A,et al.Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery[J].Surg Today,2017,47(8):994-1000.

[93] KHORANA A A,FRANCIS C W,CULAKOVA E,et al.Thromboembolism in hospitalized neutropenic cancer patients[J].J Clin Oncol,2006,24(3):484-490.

[94] KHORANA A A,KUDERER N M,CULAKOVA E,et al.Develo-pment and validation of a predictive model for chemotherapy-associated thrombosis[J].Blood,2008,111(10):4902-4907.

[95] LELEU X,RODON P,HULIN C,et al.MELISSE,a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs[J].Thromb Haemost,2013,110(4):844-851.

[96] CHALAYER E,TARDY-PONCET B,KARLIN L,et al.Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment:An observational cohort study[J].Res Pract Thromb Haemost,2018,3(1):89-98.

[97] CORNELL R F,GOLDHABER S Z,ENGELHARDT B G,et al.Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents[J].Br J Haematol,2020,190(4):555-561.

[98] TOMASELLI G F,MAHAFFEY K W,CUKER A,et al.2017 ACC Expert consensus decision pathway on management of bleeding in patients on oral anticoagulants:A report of the american college of cardiology task force on expert consensus decision pathways[J].J Am Coll Cardiol,2017,70(24):3042-3067.

[99] NEWHALL K A,SAUNDERS E C,LARSON R J,et al.Use of protamine for anticoagulation during carotid endarterectomy a meta-analysis[J].JAMA Surg,2016,151(3):247-255.

[100] DE LUCA G,PARODI G,ANTONIUCCI D.Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty.A meta-analysis[J].J Thromb Thrombolysis,2010,30(4):452-458.

[101] NOUI N,ZOGHEIB E,WALCZAK K,et al.Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device[J].Perfusion,2012,27(3):214-220.

[102] RUNGE M,M?LLER C H,STEINBRüCHEL D A.Increased Accuracy in heparin and protamine administration decreases bleeding:A pilot study[J].J Extra Corpor Technol,2009,41(1):10-14.

[103] PAPACONSTANTINOU C,R?DEGRAN K.Use of the activated coagulation time in cardiac surgery.Effects on heparin-protamine dosages and bleeding[J].Scand J Thor Cardiovasc Surg,1981,15(2):213-215.

[104] CROWTHER M A,DONOVAN D,HARRISON L,et al.Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin[J].Thromb Haemost,1998,79(6):1116-1118.

[105] GUNTHER K E,CONWAY G,LEIBACH L,et al.Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10[J].Thromb Res,2014,113(3-4):205-209.

[106] JOHANSEN M,WIKKELS? A,LUNDE J,et al.Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients.Cochrane Database of Systematic Reviews[J].Cochrane Database Syst Rev,2015,2015(7):10555.

[107] PAN R,CHENG J,LAI K,et al.Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage:a systematic review and meta-analysis[J].Neurol Sci,2019,40(4):813-827.

[108] CHAI-ADISAKSOPHA C,HILLIS C,SIEGAL D M,et al.Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal.A systematic review and meta-analysis[J].Thromb Haemost,2016,116(5):879-890.

[109] TORNKVIST M,SMITH J G,LABAF A.Current evidence of oral anticoagulant reversal:A systematic review[J].Thromb Res,2018,162(2):22-31.

[110] ALTORJAY á,SZABóé,BODA Z,et al.An international,multicenter,prospective study of a prothrombin complex concentrate,Prothromplex Total?,in anticoagulant reversal[J].Thromb Res,2015,135(3):485-491.

[111] KUSHIMOTO S,FUKUOKA T,KIMURA A,et al.Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures:A prospective,open label,single arm phase 3b study[J].Int J Hematol,2017,106(6):777-786.

[112] SCHULMAN S,GROSS P L,RITCHIE B,et al.Prothrombin complex concentrate for major bleeding on factor Xa inhibitors:A prospective cohort study[J].Thromb Haemost,2018,118(5):842-851.

[113] CONNOLLY S J,MILLING TJ J R,EIKELBOOM J W,et al.Andexanet alfa for acute major bleeding associated with factor Xa inhibitors[J].N Engl J Med,2016,375(12):1131-1141.

[114] SONG Y,WANG Z,PERLSTEIN I,et al.Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects:a randomized three-period crossover study[J].J Thromb Haemost,2017,15(11):2125-2137.

[115] UDAYACHALERM S,RATTANASIRI S,ANGKANANARD T,et al.The reversal of bleeding caused by new oral anticoagulants (NOACs):A systematic review and meta-analysis[J].Clin Appl Thromb Hemost,2018,24(9Suppl):S117- S126.

[116] LUZ L T D,MARCHAND M,NASCIMENTO B,et al.Efficacy and safety of the drugs used to reverse direct oral anticoagulants:A systematic review and meta-analysis [J].Transfusion,2017,57(7):1834-1846.

[117] THIBAULT N,MORRILL A M,WILLETT K C.Idarucizumab for reversing dabigatran-induced anticoagulation:A systematic review[J].Am J Ther,2018,25(3):333-338.

[118] POLLACK CV J R,REILLY P A,BERNSTEIN R,et al.Design and rationale for RE-VERSE AD:A phase 3 study of idarucizu-mab,a specific reversal agent for dabigatran[J].Thromb Haemost,2015,114(1):198-205.

[119] JOSEPH J,RABBOLINI D,ENJETI A K,et al.Diagnosis and management of heparin-induced thrombocytopenia:a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group[J].Med J Aust,2019,210(11):509-516.

[120] 许俊堂.肝素诱导的血小板减少症中国专家共识解读[J].中国循环杂志，2018,33(Suppl.2):S117-S120.

[121] CUKER A,AREPALLY G M,CHONG B H,et al.American Society of Hematology 2018 guidelines for management of venous thromboembolism:heparin-induced thrombocytopenia[J].Blood Adv,2018,2(2):3360-3392.

[122] WITT D M.Approaches to optimal dosing of vitamin K antagonists[J].Semin Thromb Hemost,2012,38(7):667-672.

[123] WELLS P S,FORGIE M A,SIMMS M,et al.The outpatient bleeding risk index:Validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism[J].Arch Intern Med,2003,163(8):917-920.

[124] KEARON C,AKL E A.Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism[J].Blood,2014,123(12):1794-1779.